An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

被引:272
作者
GeurtsvanKessel, Corine H. [1 ]
Okba, Nisreen M. A. [1 ]
Igloi, Zsofia [1 ]
Bogers, Susanne [1 ]
Embregts, Carmen W. E. [1 ]
Laksono, Brigitta M. [1 ]
Leijten, Lonneke [1 ]
Rokx, Casper [2 ]
Rijnders, Bart [2 ]
Rahamat-Langendoen, Janette [3 ]
van den Akker, Johannes P. C. [4 ]
van Kampen, Jeroen J. A. [1 ]
van der Eijk, Annemiek A. [1 ]
van Binnendijk, Rob S. [5 ]
Haagmans, Bart [1 ]
Koopmans, Marion [1 ]
机构
[1] Erasmus MC, Dept Virosci, Rotterdam, Netherlands
[2] Erasmus MC, Sect Infect Diseaseas, Dept Internal Med, Rotterdam, Netherlands
[3] Radboud Univ Nijmegen, Dept Med Microbiol, Med Ctr, Nijmegen, Netherlands
[4] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands
[5] RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands
关键词
D O I
10.1038/s41467-020-17317-y
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications. SARS-CoV-2 is causing a global pandemic in which the implementation of serology can support decision making in different scenarios. Here, the authors compare the outcome of eight commercially available assays to virus neutralization and discuss their use in diagnostics and exposure assessment of SARS-CoV-2.
引用
收藏
页数:5
相关论文
共 7 条
[1]   Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward [J].
Bryant, Juliet E. ;
Azman, Andrew S. ;
Ferrari, Matthew J. ;
Arnold, Benjamin F. ;
Boni, Maciej F. ;
Boum, Yap ;
Hayford, Kyla ;
Luquero, Francisco J. ;
Mina, Michael J. ;
Rodriguez-Barraquer, Isabel ;
Wu, Joseph T. ;
Wade, Djibril ;
Vernet, Guy ;
Leung, Daniel T. .
SCIENCE IMMUNOLOGY, 2020, 5 (47)
[2]   MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015 [J].
Choe, Pyoeng Gyun ;
Perera, R. A. P. M. ;
Park, Wan Beom ;
Song, Kyoung-Ho ;
Bang, Ji Hwan ;
Kim, Eu Suk ;
Kim, Hong Bin ;
Ko, Long Wei Ronald ;
Park, Sang Won ;
Kim, Nam-Joong ;
Lau, Eric H. Y. ;
Poon, Leo L. M. ;
Peiris, Malik ;
Oh, Myoung-don .
EMERGING INFECTIOUS DISEASES, 2017, 23 (07) :1079-1084
[3]   Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period [J].
Kissler, Stephen M. ;
Tedijanto, Christine ;
Goldstein, Edward ;
Grad, Yonatan H. ;
Lipsitch, Marc .
SCIENCE, 2020, 368 (6493) :860-+
[4]  
Lassauniere R, 2020, MEDRXIV, DOI [DOI 10.1101/2020.04.09.20056325, 10.1101/2020.04.09.20056325]
[5]  
Long QX, 2020, NAT MED, V26, P845, DOI [10.1038/s41591-020-0897-1, 10.1093/cid/ciaa344]
[6]   Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients [J].
Okba, Nisreen M. A. ;
Mueller, Marcel A. ;
Li, Wentao ;
Wang, Chunyan ;
GeurtsvanKessel, Corine H. ;
Corman, Victor M. ;
Lamers, Mart M. ;
Sikkema, Reina S. ;
de Bruin, Erwin ;
Chandler, Felicity D. ;
Yazdanpanah, Yazdan ;
Le Hingrat, Quentin ;
Descamps, Diane ;
Houhou-Fidouh, Nadhira ;
Reusken, Chantal B. E. M. ;
Bosch, Berend-Jan ;
Drosten, Christian ;
Koopmans, Marion P. G. ;
Haagmans, Bart L. .
EMERGING INFECTIOUS DISEASES, 2020, 26 (07) :1478-1488
[7]  
Slot E, 2020, NATURE RES